BioStock: WntResearch’s new CEO comments on his first month in the position

Development company WntResearch recently recruited the first patient for the expansion part of the ongoing phase II study, NeoFox. This coincided with Per Norlén’s first days at the helm of the company. BioStock contacted him to find out how he sees the potential of Foxy-5, and how he, with a long career as CEO of several biotech companies, wants to contribute to advancing the positions of the project.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/wntresearchs-new-ceo-comments-on-his-first-month-in-the-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se